Pilot Study on the Impact of a Home-Based Exercise Program on Inflammatory Cytokines and Quality of Life in Men with Prostate Cancer Under Active Surveillance

Crisann Moon, MSN1, Amber M. Gallegos, BS1, Bilal Sheikh, BS1, Pratap Kumar, PhD2,3, Michael Liss, MD2,3, and Darpan I. Patel, PhD1,3,4

Abstract

Objectives: This study aimed to demonstrate potential translation of pre-clinical studies to a home-based exercise intervention in mediating inflammatory cytokine markers and tumor progression in men under active surveillance for prostate cancer.

Methods: A 2-arm randomized control parallel group design was used. The exercise intervention consisted of 24 weeks of an aerobic and resistance home-based exercise program and results were compared to a waitlist control group. Data were collected at baseline and end of study for eotaxin, interferon-γ (INF-γ), interleukin-12 (IL-12), interleukin-1α (IL-1α), interleukin-5 (IL-5), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and vascular endothelial growth factor (VEGF), distanced walked during a 6-minute walk test (6MWT), body mass index, and health-related quality of life.

Results: Non-significant decreases were observed in all biomarkers, especially VEGF (pre: 125.16 ± 198.66, post: 80.29 ± 124.30, P = .06) and INF-γ (pre: 152.88 ± 312.71, post: 118.93 ± 158.79, P = .08), in the intervention group; only IL-1α (pre: 332.15 ± 656.77, post: 255.12 ± 502.09, P = .20) decreased in the control group while all other biomarkers increased from baseline to end of study. A non-significant increase in 6MWT distance was observed in the intervention group, while a decrease was seen in the control group. Significant decreases in physical function, emotional wellbeing, and total composite scale on the FACIT-F were observed in the intervention group, possibly due to the isolation restrictions of COVID-19. Physical function on the SF-36 significantly increased in the control group.

Conclusions: Future studies with powered samples are needed to confirm the trends observed for inflammatory biomarkers and functional fitness.

Keywords
prostate cancer, exercise, biomarker, quality of life, active surveillance

Introduction

The National Cancer Institute estimates that 1 in 8 men will be diagnosed with prostate cancer (PCa) in their lifetime and there are currently an estimated 3.1 million men living who have already been diagnosed in the United States.1 With a combined overall survival rate of 98% across all stages of the disease,1 many PCa survivors are often left with lingering treatment side effects, like fatigue, that can significantly impact their quality of life (QOL).2
Approximately half of all men with low-risk tumors will fall under active surveillance treatment protocols. While beneficial for most, nearly 50% progress from active surveillance to active treatment within 5 years due to tumor progression. PCa proliferation and metastasis is multifaceted and recent studies have investigated the role of inflammatory biomarkers, or cytokines, in this progression. Serum biomarkers including tumor necrosis factor-alpha (TNF-α), interleukins (IL), and vascular endothelial growth factor (VEGF), have been linked to tumor growth and metastasis in this population. These and other cytokines have been implicated in stimulating tumor progression, modulating the tumor microenvironment and developing treatment resistance. Therefore, modalities to modulate these tumor proliferative cytokines are needed.

Recent literature has shown a growing focus on lifestyle interventions that target physical activity as a modality to delay disease progression. Exercise has been shown to improve aerobic and muscular endurance, functional performance, quality of life, and increasing cancer-specific and overall survival in men with PCa. Work within our laboratory has demonstrated shifts in circulating cytokines in response to exercise in preclinical studies. Specifically, our group noted that up to 20 weeks of voluntary wheel running significantly reduced the progression to high-risk tumors in transgenic prostate tumor challenged mouse models. This reduction in tumor progression was associated with significant decreases in pro-inflammatory cytokines, such as eotaxin, interleukin (IL)-1α, IL-5, IL-12 (p40) and VEGF. While exercise interventions have demonstrated similar outcomes in clinical populations, there is a paucity of longitudinal clinical trials that demonstrate exercise efficacy in modulating biomarkers associated with tumor progression in men with PCa. We aimed to demonstrate the translational potential of our running wheel intervention to a 6-month home-based modality developed around moderate physical activity in modulating cytokines associated with tumor progression.

The primary aim of this pilot study was to investigate the impact of a home-based exercise program on biomarkers associated with tumor progression in men with PCa under active surveillance. It was hypothesized that the home-based exercise program would result in decreased levels of inflammatory biomarkers. Secondary aims sought to determine the effects of the intervention on physical function, quality of life, and body mass index (BMI).

**Methods**

**Ethics**

Ethical approval was granted by the Institutional Review Board at the University of Texas Health Science Center at San Antonio (UT Health San Antonio), located in San Antonio, Texas, for the Audie L. Murphy Memorial Veterans Administration Hospital, and the Mays Cancer Center at UT Health San Antonio. Approval was obtained on February 14, 2017 under approval number 20160604HU. Participants were informed about the nature of the study, voluntary participation, potential benefits and risks of participating in an exercise study, the use of serum specimens, and confidentiality of participant data. Written informed consent was obtained prior to enrollment and participants were given a printed copy of the consent form. The study was registered at ClinicalTrials.gov under NCT03397030.

**Randomization and Intervention Design**

The reporting of this study conforms to the CONSORT statements. This pilot study used a 2-arm randomized control parallel group design (Figure 1). Participants were randomized 1:1 into either the home exercise intervention group or the waitlist control group by the principal investigator. Recruitment took place August 2017 to November 2019 at the Mays Cancer Center and Audie L. Murphy Memorial Veterans Administration Hospital. Participants were screened for eligibility from patient records. Inclusion and exclusion criteria are found in Table 1.

Individuals meeting eligibility criteria were approached in-person during a regularly scheduled clinic visit to introduce the study. Once consented, screened, and medically cleared, baseline data were collected. Men were then randomly assigned to either the exercise intervention group or waitlist control group using a pre-specified randomization list. Participants assigned to the exercise intervention completed a 24-week, home-based exercise program while those assigned to the waitlist control group were asked to maintain normal activity with the option of obtaining the home-based exercise plan after end-of-study data collection. The frequency, interval, intensity and timing of the intervention was determined based on recommendations by the American College of Sports Medicine. Due to the nature of exercise interventions, participants were not blinded to the intervention. The size of the research team necessitated investigators to assist in the intervention, data collection and analysis; thus, researchers were not blinded.

The exercise intervention group participated in a home-based exercise program, consisting of aerobic and bodyweight-based exercises. The aerobic portion of the intervention included 5 days per week of light-to-moderate intensity (40-60% of heart rate reserve) walking for 30 minutes, for a weekly accumulated total of 150 minutes. Heart rate reserve was calculated using the Karvonen formula: maximum heart rate = 220 – age (years). Body-weight based resistance exercises focused on increasing strength of major body muscle groups. Squats, inclined push-ups, and hip thrusts were performed 3 times per week consisting of 3 sets of 15 reps for each exercise. A FitBit Flex activity tracker (Fitbit Inc, San Francisco, CA, USA) was issued to each exercise group participant to help track physical activity. Participants met with a research team member for an in-person orientation visit,
where exercises were demonstrated, the FitBit account was set up and the participant were shown how to use the device, and participants were taught how to measure radial pulse to ensure they were in the target heart rate zone during exercise. Each participant in the intervention arm received a booklet with information on target heart rate for the 30-minute aerobic portion. Participants did not progress aerobic nor resistance intensity or frequency during the study. The remainder of the intervention was performed remotely at home until participants returned for the in-person final data collection. Participants were contacted if no FitBit activity had been reported for 1 week.

Cytokine Collection and Analysis

Blood samples were collected into 8-mL serum separating tubes from the antecubital space via venipuncture at baseline and end of study. End of study serum samples were collected within 7 days of participants completing the study. The samples were spun down at 1500XG for 15 minutes. Serum was placed into 600 μL aliquots and frozen at −80 °C until analysis. Serum cytokines (eotaxin, INF-γ, IL-12, IL-1α, IL-5, IL-6, TNF-α, and VEGF) were analyzed using an 8-protein multiplex assay (Millipore Sigma, Billerica, MA). Samples were assayed in duplicate and averaged.
BMI

Height (cm) and weight (kg) were collected at baseline and end of study to calculate BMI.

Functional Fitness Assessments

Functional fitness was assessed using a 6-minute walk test (6MWT) at baseline and end of study as previously described.17 Participants were instructed to walk as quickly as possible between 2 markers on the floor placed 40 m apart for 6 minutes. Total distance was calculated in meters. A difference of 14-40 m has been suggested as a range for minimal clinically important difference in the 6MWT.18

Health-Related Quality of Life

Outcome Measurements

To measure health-related quality of life and fatigue, all participants completed the 36-Item Short Form Health Survey (SF-36) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) surveys at baseline and end-of-study. The SF-36 assessed 8 area of quality of life including physical functioning, role functioning, social functioning, physical pain, general health, mental health, and emotional health. The SF-36 has been previously validated and has a well-established reliability.19 The FACIT-F served as a measurement of participant quality of life, encompassing domains of physical, social/family, emotional, functional well-being and fatigue. Reliability and validity for the FACIT-F have been previously established.20

Statistical Analyses, Sample Size Determination and Data Transformations

Statistical analyses were performed using SPSS for Window version 28.0 (IBM Corporation). Participants lost to attrition were not replaced. The study data set is available upon request from the corresponding author. Sample size calculation was not conducted, however based on prior studies, it was determined that 15 participants in each arm would be feasible to complete this pilot investigation21,22 Due to small sample size, serum biomarker outliers were not excluded from analysis. Only participants with both baseline and final serum samples were included in biomarker analysis.

Psychosocial and fatigue measures were scored using standardized calculations from the respective organizations to create continuous composite domain scales for both the SF-36 and FACIT-F and a total composite score for the FACIT-F.19,20 Raw SF-36 item scores were re-coded on a scale from 0-100 and individual domains were created from averaging specific questions based the percentage of questions answered.23 A higher scale score was associated with better reported quality of life. Similarly, raw FACIT-F items were re-coded based on developer’s guidelines and averaged to create individual scales based on the percentage of questions answered. Possible physical wellbeing, social/family wellbeing, and functional wellbeing scores ranged from 0-28, emotional wellbeing 0-24, fatigue subscale from 0-52, and composite scores from 0-160. Higher scores on FACIT-F scales and composite score indicated better quality of life. Scale scores within each study arm were analyzed using paired t-tests at baseline and end-of-study, while independent t-tests evaluated differences between the intervention and control groups for the same measures at the same time points. Missing questionnaire data were managed based on the percentage of missing responses per scale and recommendations based on the individual developers.21,22

Descriptive statistics were performed and are presented at mean ± standard deviation. Independent and paired sample t-tests were conducted to determine between group and within group comparisons for all outcome variables. Significance for all analyses was P ≤ .05.

Results

A total of 27 men were consented and enrolled in the study with 15 in the intervention arm and 12 in the control group.

Table 1. Inclusion and Exclusion Criteria.

| Inclusion criteria | Exclusion criteria |
|--------------------|-------------------|
| Men >40 years old  | Severe cardiac disease (NYHA class III or greater) |
| Diagnosed prostate cancer | Angina |
| Under active surveillance at time of study | Severe osteoporosis |
| Gleason score of 3+3 | Uncontrolled hypertension (>160/95 mmHg) |
| Able to provide consent for study participation | Uncontrolled sinus tachycardia (>120 bpm) |
| Cardiac comorbidities | Uncontrolled diabetes |
| Uncontrolled pain | Uncontrolled pain |
| Cognitive impairment | Cognitive impairment |
| History of falls due to balance impairment | Severe neuromusculoskeletal conditions that would prevent walking exercise |
Participant flow through the study has been provided in Figure 1. Nine men completed the exercise intervention (40% attrition) while 6 men completed the study in the control group (50% attrition). One participant in the intervention group completed less than 50% of the baseline FACIT-F questionnaire and the test was not scored in accordance with the developer’s recommendation for missing data. Three participants in the intervention group completed the study but did not provide responses to the SF-36 and FACIT-F at end-of-study. Two participants in the control group completed the quality of life and fatigue questionnaires but were unable to complete the final data visit for serum biomarker collection, BMI and 6MWT due to institutional COVID-19 restrictions. Demographic information for both groups at baseline has been outlined in Table 2. No adverse events were reported.

### Cytokine Analysis

All proteins analyzed fell within normal ranges of the assay kit. Paired t-tests revealed no statistically significant differences in serum cytokine levels from baseline to end-of-study in either the intervention group or control (Table 3). However, all cytokine concentrations decreased from baseline to end-of-study in the exercise group. In contrast, only 1 cytokine in the control group decreased during the same period, with IL-1α decreasing by 23.2%. All other cytokines in the control group increased, with the largest effect size observed for VEGF ($d = .59$) and INF-γ ($d = .52$). Independent t-tests comparing intervention and control groups found no significant difference at baseline or end-of-study (Table 3).

### Body Mass Index

No significant differences were observed in within group or between group comparisons. Differences in BMI for the intervention group at baseline (26.27 ± 2.80) and end-of-study

#### Table 2. Study Demographics.

| Characteristic | Exercise intervention | Control group | p   |
|----------------|-----------------------|---------------|-----|
| Age (years)    | 72.78 ± 5.31          | 75.17 ± 11.44 | .30 |
| Weight (kg)    | 86.56 ± 6.37          | 86.00 ± 7.59  | .44 |
| BMI (kg/m²)    | 26.82 ± 2.80          | 28.27 ± 2.52  | .41 |
| Race           |                       |               |     |
| White          | 4                     | 5             |     |
| Black          | 3                     | 0             |     |
| Hispanic       | 2                     | 1             |     |

#### Table 3. Inflammatory Cytokine Comparison.

|                | Intervention group | Control group |
|----------------|--------------------|---------------|
|                | Baseline           | End of study  | p   | d   |
| Eotaxin        | 118.21 ± 90.30     | 110.22 ± 97.24 | .35 | .13 |
| INF-γ          | 152.88 ± 312.71    | 118.93 ± 258.79 | .08 | .52 |
| IL-12          | 28.69 ± 32.06      | 23.92 ± 19.38  | .16 | .36 |
| IL-1α          | 78.76 ± 183.30     | 65.55 ± 146.70 | .16 | .35 |
| IL-5           | 18.07 ± 40.84      | 16.82 ± 37.65  | .15 | .38 |
| IL-6           | 23.68 ± 45.66      | 21.24 ± 45.18  | .19 | .31 |
| TNF-α          | 24.58 ± 35.40      | 19.71 ± 20.76  | .21 | .29 |
| VEGF           | 125.16 ± 198.66    | 80.29 ± 124.30 | .06 | .59 |

|                | Intervention       | Control        |
|----------------|--------------------|----------------|
|                | Baseline           | End of study   | p   | d   |
| Eotaxin        | 118.21 ± 90.32     | 185.41 ± 237.22 | .16 | −.60|
| INF-γ          | 152.88 ± 312.71    | 220.07 ± 283.51 | .15 | −.62|
| IL-12          | 28.69 ± 32.06      | 24.06 ± 27.06  | .48 | .03 |
| IL-1α          | 78.76 ± 183.30     | 332.15 ± 656.77 | .20 | .50 |
| IL-5           | 18.07 ± 40.84      | 151.60 ± 300.39 | .20 | .50 |
| IL-6           | 23.68 ± 45.66      | 95.27 ± 188.89 | .19 | −.51|
| TNF-α          | 24.58 ± 35.40      | 29.52 ± 41.41  | .13 | −.68|
| VEGF           | 125.16 ± 198.66    | 115.48 ± 213.25 | .18 | −.54|

#### Table 3 Continued

|                | Intervention       | Control        |
|----------------|--------------------|----------------|
|                | Baseline           | End of study   | p   | d   |
| Eotaxin        | 118.21 ± 90.32     | 110.22 ± 97.24 | .35 | .13 |
| INF-γ          | 152.88 ± 312.71    | 118.93 ± 258.79 | .08 | .52 |
| IL-12          | 28.69 ± 32.06      | 23.92 ± 19.38  | .16 | .36 |
| IL-1α          | 78.76 ± 183.30     | 65.55 ± 146.70 | .16 | .35 |
| IL-5           | 18.07 ± 40.84      | 16.82 ± 37.65  | .15 | .38 |
| IL-6           | 23.68 ± 45.66      | 21.24 ± 45.18  | .19 | .31 |
| TNF-α          | 24.58 ± 35.40      | 19.71 ± 20.76  | .21 | .29 |
| VEGF           | 125.16 ± 198.66    | 80.29 ± 124.30 | .06 | .59 |

INF-γ = interferon-γ, IL-12 = interleukin-12, IL-α = interleukin-α, IL-5 = interleukin-5, IL-6 = interleukin-6, TNF-α = tumor necrosis factor-α, VEGF = vascular endothelial growth factor.
(26.82 ± 3.42) were not statistically significant, (t(5) = −1.06, P = .17). The control group analyses returned non-significant results for BMI from baseline (27.10 ± 3.12) to end-of-study (27.43 ± 2.22), (t(2) = −.64, P = .29). No other significant correlations were found for BMI and serum biomarkers for either group.

**Functional Fitness**

No significant differences were observed within group or between groups. Though not significant, an increase in 6MWT distance was observed in the intervention group (baseline: 451.19 ± 95.95; final: 484.16 ± 78.59; P = .24; d = .43) compared to a decrease in the control group (baseline: 414.06 ± 65.99; final: 411.77 ± 25.84; P = .47; d = .04 ). Further, between group comparisons at the end of study found the intervention group travelled farther than the control group (intervention: 414.06 ± 65.99; control: 411.77 ± 25.84; P = .47; d = 1.13 ).

**Quality of Life and Fatigue**

Within-group FACIT-F analyses are presented in Table 4. A significant decrease in physical wellbeing, emotional wellbeing, and total composite score were observed in the intervention group from baseline to end-of-study. No significant changes were seen in the control group. Between-group comparison (Table 5) did not return any significant differences for FACIT-F at baseline nor end-of-study. SF-36 within-group comparisons are also found in Table 5. No significant changes were observed in the intervention group. Physical function in the control group significantly increased from baseline to end-of-study. Between group analysis (Table 5) showed a significant difference in physical functioning and emotional functioning at baseline only, with higher scores observed in the intervention group. No other significant difference was found.

**Discussion**

The primary purpose of this study was to determine the effects of a home-based exercise program on circulating cytokines associated with tumor progression in men with PCa under active surveillance. Despite challenges of COVID-19 restrictions, 9 participants in the intervention group and 6 participants in the control group completed the study. Although not statistically significant, a decrease across all biomarkers followed the same trend previously seen in the murine exercise study in our laboratory, lending support for the translational nature of our intervention to the clinical setting.

**Table 4. Health-Related Quality of Life Within Group Comparisons from Baseline to End of Study.**

| FACIT-F | Intervention group | Control group |
|--------|-------------------|---------------|
|        | Baseline | End of study | p   | d    | Baseline | End of study | p   | d    |
| PWB    | 26.0 ± 1.9 | 24.4 ± 3.4 | .04 | 1.06 | 23.7 ± 5.3 | 24.2 ± 3.1 | .31 | −.21 |
| SWB    | 20.0 ± 6.6 | 17.2 ± 7.0 | .07 | .80  | 19.7 ± 7.7 | 22.1 ± 7.5 | .08 | −.66 |
| EWB    | 23.0 ± 1.0 | 18.8 ± 3.6 | .04 | 1.06 | 21.0 ± 4.2 | 20.7 ± 3.2 | .42 | .09  |
| FWB    | 20.8 ± 5.5 | 19.2 ± 8.5 | .25 | .33  | 24.1 ± 7.5 | 24.7 ± 4.5 | .40 | −.11 |
| Fatigue| 45.2 ± 4.9 | 40.8 ± 11.0| .11 | .66  | 40.5 ± 9.1 | 42.3 ± 10.2| .10 | −.61 |
| Composite | 135.0 ± 17.1 | 120.4 ± 30.3 | .05 | .99  | 129.0 ± 32.1 | 133.9 ± 26.5 | .20 | −.38 |

| SF-36 | Intervention group | Control group |
|-------|-------------------|---------------|
|        | Baseline | End of study | p   | d    | Baseline | End of study | p   | d    |
| PF     | 84.2 ± 15.9 | 85.0 ± 18.4 | .43 | −.07 | 65.8 ± 23.1 | 84.2 ± 19.6 | .005 | −1.63 |
| RLPH   | 37.5 ± 49.4 | 50.0 ± 54.8 | .18 | −.41 | 20.8 ± 40.1 | 58.3 ± 46.6 | .08  | −.69 |
| RLEH   | 41.7 ± 32.9 | 66.7 ± 42.2 | .10 | −.60 | 58.3 ± 41.8 | 83.3 ± 40.8 | .06  | −.76 |
| EF     | 69.2 ± 15.3 | 65.0 ± 30.7 | .10 | .21  | 52.5 ± 30.3 | 59.2 ± 22.0 | .07  | −.72 |
| EMWB   | 88.0 ± 11.3 | 82.0 ± 13.1 | .31 | .52  | 82.7 ± 14.9 | 80.7 ± 22.3 | .29  | .24  |
| SFUN   | 87.5 ± 7.9 | 79.2 ± 24.6 | .13 | .36  | 85.4 ± 24.3 | 81.3 ± 29.3 | .09  | .65  |
| Pain   | 75.8 ± 26.5 | 69.2 ± 27.5 | .17 | .43  | 77.1 ± 21.4 | 79.2 ± 19.6 | .38  | −.13 |
| GH     | 83.3 ± 8.8 | 72.5 ± 18.1 | .09 | .65  | 80.0 ± 11.0 | 78.3 ± 17.8 | .33  | .19  |

PWB = physical wellbeing, SWB = social/family wellbeing, EWB = emotional wellbeing, FWB = functional wellbeing. For SF36: PF = physical functioning, RLPH = role limitations-physical health, RLEH = role limitations-emotional health, EF = energy/fatigue, EMWB = emotional wellbeing, SFUN = social functioning, GH = general health. Higher scores on all scales indicate higher functioning.
population. Our results are similar to findings of a home-based exercise intervention by Hvid et al. who observed a non-statistically significant decrease in mean IL-6 after 24 months; however, this study found an increase TNF-α within the same time parameters. This discrepancy may be due to differences in exercise prescription protocol. Our program utilized the minimum physical activity guidelines as prescribed by the ACSM, with participants completing 150 minutes of activity over 5 days per week, for 24 weeks, whereas participants completed interval training 3 days per week for 24 months in Hvid et al. study.

Body composition plays a major role in PCa risk and progression, due to the impact that adiposity has in manipulating androgen signaling and systemic inflammation. A review by Lopez et al. found that a combination of resistance and aerobic exercise was the most effective form of exercise intervention in reducing body fat. Although our intervention included both resistance and aerobic components, we did not observe a change in BMI in either group. While our results do not agree with the literature, the increase in BMI seen in our study is consistent with findings from Gaskin et al. and Villumsen et al. who both observed an increased distance walked during a 6MWT for community-based exercise interventions when compared to usual care. Together with the results from our study, these findings suggest that the use of a home-based intervention may have clinical relevance in preserving or improving physical function in prostate cancer during active surveillance.

Finally, quality of life and fatigue results contradict published studies. Physical wellbeing, emotional wellbeing, and overall composite scores on the FACIT-F decreased in the intervention group while only a small decrease in emotional wellbeing was observed in the control group from baseline to end-of-study. These findings contrast with results from a systematic review and meta-analysis by Vashistha et al. that...
found exercise significantly improved fatigue symptoms and increased quality of life in men with PCa. Similarly, our results were different from Kang et al. who found an increase in general quality of life during a high-intensity interval training program for men under active surveillance for prostate cancer. When evaluating the subscales, the largest decreases in the intervention group were social and emotional wellbeing on the FACT-F. Similarly, emotional wellbeing and social functioning were also 2 scales on the SF-36 that decreased in the intervention group but not in the control group. As this study took place during the COVID-19 pandemic, the isolation and breakdown of social activities could help explain some variance, although the same downward trend was not seen in the social wellbeing scale for the control group.

Interpretation of our study outcomes need to be evaluated in the context of the limitations of this study. Due to the COVID-19 pandemic, we experienced a higher-than-expected attrition due to changes in participant availability and local guidelines limiting in-person study visits. Statistical analysis and generalizability were constrained by our small sample size, making comparison to similar studies difficult. Information about participant disease stage (Gleason score, prostate-specific antigen levels, and time on active surveillance) and comorbidities that may account for chronic inflammation were not collected, which may have influenced biomarker levels. Although the FitBit devices were used to gauge adherence to the exercise intervention, the trackers did not have heart rate monitoring capabilities; thus, information on intensity and self-reported physical activity was not collected during the study. This information may have allowed further analysis by physical activity level to determine if exercise outside the study may have impacted the findings.

Despite these limitations, the clinically significant increase in functional fitness and decreased inflammatory biomarkers suggests that a home-based exercise program may be effective in reducing inflammatory cytokines and increasing functional capacity in men with PCa. Additionally, these biomarker changes add to the growing body of knowledge of physiological mechanisms underlying observed outcomes in exercise oncology. Future studies with statistically powered samples would be needed to confirm the non-statistically significant trends observed in the exercise group for inflammatory biomarker and 6MWT.

Conclusion

The results of this study suggest that men with prostate cancer on active surveillance can potentially benefit from a home-based exercise program. Our data suggest that a home-based exercise program can modulate inflammatory cytokines associated with tumor progression while also positively impacting physical function and quality of life. Though not significant, the findings of our study may have clinical implications. Future studies are needed to confirm these findings in a powered sample.

Acknowledgments

The authors would like to thank the men who volunteered their time and effort for this study. Without willing volunteers like the participants in the study, we would never be able to understand the clinical impact of exercise. The authors would also like to acknowledge the Bioanalytics and Single-Cell (BASiC) Core at UT Health San Antonio’s Greehy Children’s Cancer Research Institute in support of the multiplex analysis performed for this study.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

This study was funded by an internal research grant from the School of Nursing Advisory Council at the University of Texas Health Science Center and a grant from the United States Department of Education (P031S150048). The National Cancer Institute designated UT Health San Antonio Mays Cancer Center also supported this work (P30CA541740D).

Ethical Approval

Ethical approval was granted by the Institutional Review Board at the University of Texas Health Science Center at San Antonio (UT Health San Antonio), the Audie L. Murphy Memorial Veterans Administration Hospital, and the Mays Cancer Center at UT Health San Antonio (#20160604HU). Participants were informed about rights and informed consent was obtained prior to enrollment and given a written copy of the consent form. The study was registered at ClinicalTrials.gov under NCT03397030.

ORCID iD

Crisann Moon https://orcid.org/0000-0002-4967-5952

References

1. National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER) cancer stat facts: Prostate cancer; 2021.
2. Keough JWL, MacLeod RD. Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: A systematic review. J Pain Symptom Manag. 2012;43(1):96-110. doi:10.1016/j.jpainsymman.2011.03.006.
3. Auffenberg G, Lane BR, Miller DC. Practice- vs physician-level variation in use of active surveillance for men with low-risk prostate cancer. JAMA Surgery. 2017;152(10):978-980. doi:10.1001/jamasurg.2017.1586.
4. Timilshina N, Komisarenko M, Martin LJ, et al. Factor associated with discontinuation of active surveillance among men.
with low-risk prostate cancer: A population-based study. J Urol. 2021;206(4):903-913. doi:10.1097/JU.0000000000001903.

5. Yang J, Hong-Fei W, Qian L-X, et al. Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF-receptor-3 in prostate cancer tissue are associated with tumor progression. Asian J Androl. 2006;8:169-175. doi:10.1111/j.1745-7262.2006.00120.x.

6. Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: The role of interleukin 6 (IL-6). BJU Int. 2014;113(6):986-992. doi:10.1111/bju.12452.

7. Archer M, Dogra N, Kyprianou N. Inflammation as a driver of prostate cancer metastasis and therapeutic resistance. Cancers. 2020;12(10):1-24. doi:10.3390/cancers12102984.

8. Mao C, Ding Y, Xu N. A double-edged sword role of cytokines in prostate cancer immunotherapy. Front Oncol. 2021;11:1-13. doi:10.3389/fonc.2021.688489.

9. Wokesa A, Harrison M, Watson RW. Physical activity and its mechanical effects on prostate. Prostate Cancer Prostatic Dis. 2015;18:197-207. doi:10.1038/pcan.2015.9.

10. Bonn SE, Sjolander A, Lagerros YL, et al. Physical activity and survival among men diagnosed with prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014;24(1):57-65. doi:10.1158/1055-9965.EPI-14-0707.

11. Galvao DA, Taaffe DR, Spry N, et al. Exercise preserves physical function in prostate cancer patients with bone metastases. Med Sci Sports Exerc. 2018;50(3):393-399. doi:10.1249/MSS.0000000000001454.

12. Patel DI, Abuchowski K, Sheikh B, RivasMusi PN, Kumar AP. Exercise preserves muscle mass and force in a prostate cancer mouse model. Eur J Transl Myol. 2019;29(4):328-333. doi:10.4081/ejtm.2019.8520.

13. Khorasani N, Stoner L, Farajivaf A, Hanson ED. Exercise training, circulating cytokine levels, and immune function in cancer survivors: A meta-analysis. Brain Behav Immun. 2019;81:92-104. doi:10.1016/j.bbi.2019.08.187.

14. Schulz KF, Altman DG, Moher D. CONSORT Group. BMJ. 2010:332-340.

15. American College of Sports Medicine. ACSM's Guide to Exercise and Cancer Survivorship. Human Kinetics; 2012.

16. Karvnonen M, Kentala E, Mustala O. The effects of training on exercise and Cancer Survivorship. Med Sci Sports Exerc. 2018;50(3):393-399. doi:10.1249/MSS.0000000000001454.

17. van Leeuwen M, Kieffer JM, Efficace F, et al. International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer. Health Qual Life Outcome. 2017;15(97):1-14. doi:10.1186/s12955-017-0670-4.

18. Yellen SB, Cell DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manag. 1997;13(2):63-74. doi:10.1016/s0885-3924(96)00274-6.

19. Julious S. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat. 2005;4(4):287-291. doi:10.1002/pst.185.

20. Johanson G, Brooks GP. Initial scale development: Sample size for pilot studies. Edu Psychol Meas. 2010(70):394-400. doi:10.1177/001649509355692.

21. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A Users’ Manual. Boston: The Health Institute; 1994.

22. Hvid T, Lindegaard B, Windling K, et al. Effect of a 2-year home-based endurance training intervention on physiological function and PSA doubling time in prostate cancer patients. Cancer Causes Control. 2016(27):165-174. doi:10.1007/s10552-015-0694-1.

23. Hoda MR, Theil G, Mohammed N, FischerFornara KP. The adipocyte-derived hormone leptin has proliferative actions on androgen-resistant prostate cancer cells linking obesity to advanced stages of prostate cancer. J Oncol. 2012. doi:10.1155/2012/280386.

24. Fuji T, Hayashi T, Matsushita M, Uemura M, Nonomura N. Obesity, inflammation, and prostate cancer. J Clin Med. 2019;8. doi:10.3390/jcm8020201.

25. Lopez P, Newton RU, Taaffe DR, et al. Interventions for improving body composition in men with prostate cancer: A systematic review and network meta-analysis. Med Sci Sports Exerc. 2021. doi:10.1249/MSS.0000000000002843.

26. Restrepo BJ. Obesity prevalence among U.S. adults during the COVID-19 pandemic. Am J Prev Med. 2022. doi:10.1016/j.amepre.2022.01.012.

27. Campos C, Sotomayor P, Jerez D, et al. Exercise and prostate cancer: From basic science to clinical applications. Prostate. 2018;78(9). doi:10.1002/pros.23502.

28. Gaskin C, Fraser SF, Owen PJ, Craike M, Orellana L, Livingston PM. Fitness outcomes from a randomised controlled trial of exercise training for men with prostate cancer: the ENGAGE study. BJU Int. 2019;124(4):600-608. doi:10.1111/bju.14782.

29. Vashistha V, Singh B, Kaur S, Prokop LJ, Kaushik D. The effects of exercise on fatigue, quality of life, and psychological function for men with prostate cancer: systematic review and meta-analyses. Eur Urol Focus. 2016;10:972-980. doi:10.1016/j.euruxf.2016.0543-6.

30. Villumsen B, Jorgensen MG, Frystyk J, Hordam B, Borre M. Home-based ‘exergaming’ was safe and significantly improved 6-min walking distance in patients with prostate cancer: a single-blinded randomised controlled trial. BJU Int. 2019;124(4):814-822. doi:10.1111/bju.14782.